These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34807761)

  • 1. Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
    Carvalhaes CG; Sader HS; Streit JM; Castanheira M; Mendes RE
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0166721. PubMed ID: 34807761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
    Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
    J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
    Belley A; Arhin FF; Moeck G
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and risk factors of methicillin-resistant
    Huang L; Zhang R; Hu Y; Zhou H; Cao J; Lv H; Chen S; Ding S; Chen G
    Antimicrob Resist Infect Control; 2019; 8():90. PubMed ID: 31164979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
    Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
    Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activity.
    Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Chemother; 2018 Sep; 30(5):280-289. PubMed ID: 30843778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment.
    Di Cecco C; Monticelli J; Di Bella S; Di Maso V; Luzzati R
    J Chemother; 2024 Feb; 36(1):31-34. PubMed ID: 37602423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci.
    Yan Q; Karau MJ; Patel R
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):348-350. PubMed ID: 29678300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP) Bloodstream Infection Annual Report 2022.
    Coombs GW; Daley DA; Shoby P; Mowlaboccus S
    Commun Dis Intell (2018); 2023 Nov; 47():. PubMed ID: 37968068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).
    Pfaller MA; Sader HS; Castanheira M; Flamm RK; Mendes RE
    J Antimicrob Chemother; 2018 Apr; 73(4):916-922. PubMed ID: 29294031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.
    Meyer KA; Deraedt MF; Harrington AT; Danziger LH; Wenzler E
    Int J Antimicrob Agents; 2019 Aug; 54(2):197-201. PubMed ID: 31034937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).
    Sader HS; Moet GJ; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
    Crotty MP; Krekel T; Burnham CA; Ritchie DJ
    J Clin Microbiol; 2016 Sep; 54(9):2225-32. PubMed ID: 26962092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents.
    Hsueh PR; Chen WH; Teng LJ; Luh KT
    Int J Antimicrob Agents; 2005 Jul; 26(1):43-9. PubMed ID: 15975769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of daptomycin & linezolid against methicillin resistant Staphylococcus aureus & vancomycin resistant enterococci isolated from hospitalized cases in Central India.
    Chitnis S; Katara G; Hemvani N; Pareek S; Chitnis DS
    Indian J Med Res; 2013 Jan; 137(1):191-6. PubMed ID: 23481072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.